Milan, May 15, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumor cancers today announces the appointment of Mike Cogswell as Chairman of the board and the appointment of Mike Maszy as Non-Executive Director. Mike Cogswell brings over 34 years of proven…
Milan, April 30, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumor cancers today announces the name change to BetaGlue Therapeutics, the new trading name of the Company, and also a new brand identity. Alongside this, the Company also announces Yntradose®,…
Milan, March 4, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products in the field of loco-regional radiotherapy to treat solid tumor cancers called ‘BAT-90’, today announced that it has been successful in its application for a €10m EIC Accelerator award. The European Innovation Council (EIC)…
Milan, January 15, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products with a primary focus in the field of loco- regional radiotherapy to treat solid tumor cancers, today announced the appointment of Salvatore Calabrese as the Company’s Chief Financial Officer. Salvatore brings a wealth of…
The Board of Directors welcomes new Board Members Giovanni Cerutti and Luca Melindo who will support the company's future growth The Ordinary Shareholder’s Meeting of BetaGlue Technologies appointed the new Board of Directors: Colin Story, Giovanni Cerutti and Luca Melindo have been appointed Directors of the Company, while Diana Saraceni, Claudio Giuliano, Michel Therin are…
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas
According to the article featured in the international peer-reviewed journal, BAT-90 could be considered a safe and innovative therapeutic option for unresectable solid liver tumors BetaGlue Technology’s Antonino Amato and Pier Luigi Carriero, together with Gordon McVie (King's College London), Giovanni Paganelli (Istituto Romagnolo Studio Tumori, IRCCS), Roberto Cianni and Giuseppe Maria Ettore (San Camillo/Forlanini…
The raised capital will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90 , thus opening a new chapter in the fight against cancer BetaGlue Technologies has closed a EUR 10 million equity financing round : Fin Posillipo (Petrone Group), Kairos Partners SGR, LIFTT (Venture Capital led by Stefano Buono, founder…
The first clinical findings have shown that BAT-90 makes it possible to treat onlythe area where the tumor is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety BetaGlue Technologies has enrolled the first patient in a clinical trial withBAT-90 , the company’s cancer radiotherapy platform. The first clinical findings…
BetaGlue (www.betaglue.com), an innovative Italian company in the field of interventional oncology today announced the appointment of its new Board of Directors, composed by investors representatives, independent industry experts and company CEO. New members of the board are Riccardo Palmisano, Company’s Chairman and Geoffroy De Ribains, as independent Board member. Antonino Amato, CEO of the company, Diana Saraceni (Panakes Partners)…
